Frogger Token Positioned to Lead the Next Memecoin Run!
London, UK, May 21, 2025 (GLOBE NEWSWIRE) — Frogger enters a space that has already seen great successes from frog-themed meme coins such as Pepe ($PEPE) Apu Apustaja ($APU) FWOG ($FWOG) HOPPY ($HOPPY) and many more!
Frog memecoins are established within the decentralised space and have been consistently set in motion by high profile references to the Pepe meme. These mentions have been made by the likes of Elon Musk and even Donald Trump. Frogger is setting the trend and aligning itself in a similar manner which led these memecoins to billions in market cap.
A key differentiator for Frogger is its broad token distribution—less than 55% is held by the top 100 holders, with Ethereum founder Vitalik Buterin as the largest holder. This distribution resembles other memecoins such as $DOGE $PEPE and $SHIBA before they went parabolic.
Recognition and Growing Credibility
Frogger has already captured attention and recognition amongst multiple social media influencers and content creators. This was expected as Frogger has History, Culture and Relevance.
The 1981 arcade Frogger game was one of the most popular and most sold out during the Arcade Era grossing $135million in North America for Sega/Gremlin becoming their most successful release.
Additionally Vitalik Buterin is the top holder having acquired Frogger organically. What's more is the Pepe Deployer is also one of the top 100 holders garnering watchful eyes within domain.
Frogger isn't just riding a wave—it is the wave. With deep roots in internet lore, cultural cachet from day one, this isn't another memecoin—it's a movement.
Tokenomics Read More Digitoads is one of the best ICO in 2023 - The Cryptonomist
Frogger's decentralized ethos and simple tokenomics mirror those of other major memecoins like $SHIBA, $PEPE, $DOGE, $WIF, and $FLOKI.
A rapidly growing community, zero tax and a burnt liquidity pool.
Thanks to its minimalist contract design, transactions are seamless and scalability is built-in, ensuring new holders can join easily—crucial in the swift-moving meme coin market.
Will Frogger be the next Frog meme to hit BILLIONS in market cap?
Historically, frog memes have proven to be some of the most powerful and enduring symbols in the meme coin world. Take $Pepe, for example — it dominated the last cycle, soaring to a fully diluted valuation exceeding $12 billion. This undeniable success highlights one clear truth: frog-themed tokens have a unique ability to capture the hearts of retail investors.
So, the question is — could Frogger be the defining frog meme of this cycle? With its community-driven story and a rapidly growing base of over 2,000 holders, Frogger is poised to be far more than just another meme coin. It represents an evolving narrative that every participant can shape, potentially leading the next wave of meme coin culture.
Get Involved with Frogger
Frogger offers something new in the Memecoin space. An evolving frog-themed cryptocurrency attracting new investors and arcade game lovers from the 80s and 90s. The story continues to get better creating a dynamic experience.
Find out for yourself. Join the community. Be a part of something special.
Website | X | Telegram
Disclaimer:
The information provided in this release is not investment advice, financial advice, or trading advice. It is recommended that you practice due diligence (including consultation with a professional financial advisor) before investing or trading securities and cryptocurrency.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
By GlobeNewswire Published on June 2, 2025, 10:15 IST Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS) 1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting 1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, including breast, colon, lung and pancreatic and is investing in multiple manufacturing facilities, with industry-leading infrastructure to accelerate delivery of RLTs to patients Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) with a positive trend in overall survival (OS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) treated with radioligand therapy (RLT), Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan), in combination with standard of care (SoC) versus SoC alone1. In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3. Almost all mHSPC patients ultimately progress to metastatic castration-resistant prostate cancer (mCRPC)4. There is a need for additional treatment options with novel mechanisms of action that further delay progression, prolong OS and improve disease control compared to the current SoC, while showing a favorable safety and tolerability profile. 'The progression from metastatic hormone-sensitive prostate cancer to castration-resistant disease remains a formidable challenge that can profoundly impact the survival of patients,' said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer at Novartis. 'These results further strengthen our confidence in Pluvicto as a PSMA-targeted radioligand therapy. Following the recent FDA approval based on the PSMAfore trial in metastatic castration-resistant prostate cancer, these data suggest using it in an earlier disease setting could advance care and address a significant unmet need for hormone-sensitive prostate cancer patients.' This is the third positive read-out for Pluvicto in a Phase III trial, following the VISION and PSMAfore studies5,6. Results from PSMAddition in mHSPC show potential for treatment in an earlier setting with Pluvicto, which was recently granted US Food and Drug Administration (FDA) approval for earlier use in mCRPC, based on results from PSMAfore1,2. Novartis is harnessing the innovation of world-class scientists, strategic partnerships and one of the industry's most competitive pipelines to explore the potential of new, targeted therapies and precision medicine platforms to address the greatest unmet needs in prostate cancer. Data will be presented at an upcoming medical meeting and, based on FDA feedback, will be submitted for regulatory review in the second half of the year. About PSMAddition study PSMAddition (NCT04720157) is a Phase III, open-label, prospective, 1:1 randomized study comparing the efficacy and safety of Pluvicto in combination with SoC (ARPI + ADT) vs. SoC alone in adult patients with PSMA-positive mHSPC3. Patients randomized to the SoC alone arm are allowed to crossover to receive Pluvicto, upon confirmation of radiographic progression by blinded independent review committee (BIRC) and per the discretion of the treating physician3. The primary endpoint is rPFS, defined as the time to radiographic progression by PCWG3-modified RECIST V1.1 (as assessed by BIRC) or death3. The key secondary endpoint of OS is defined as time to death due to any cause3. About Pluvicto™ (INN: lutetium (177Lu) vipivotide tetraxetan) Pluvicto is an intravenous RLT that combines a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177)5,7. After administration into the bloodstream, Pluvicto binds to PSMA-expressing target cells, including prostate cancer cells that express PSMA, a transmembrane protein5,7. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells, disrupting their ability to replicate and/or triggering cell death7. Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC1. Novartis is investigating Pluvicto in earlier stages of disease, including oligometastatic prostate cancer (PSMA-DC, NCT05939414). Novartis and radioligand therapy (RLT) Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells, anywhere in the body8,9. Novartis is investigating a broad portfolio of RLTs, exploring new isotopes, ligands and combination therapies to look beyond gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and prostate cancer and into breast, colon, lung and pancreatic cancer. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites. To support growing demand for RLTs, we have expanded production capabilities in Millburn (NJ), Zaragoza (Spain), Ivrea (Italy) and a state-of-the-art facility in Indianapolis (IN). In Carlsbad (CA), Novartis is establishing its third US-based RLT manufacturing site to support expanded use of RLTs, create resiliency in its manufacturing network and optimize the delivery of medicines to patients on the West Coast. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'may,' 'could,' 'trend,' 'potentially,' 'upcoming,' 'progression,' 'progress,' 'investigating,' 'investing,' 'look beyond,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Pluvicto, or regarding potential future revenues from Pluvicto. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Pluvicto will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Pluvicto will be commercially successful in the future. In particular, our expectations regarding Pluvicto could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. References Data on file. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2025. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition). identifier: NCT04720157. Updated March 5, 2025. Accessed June 2, 2025. Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy. ESMO Open 2023l doi: 10.1016/ Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi: 10.1056/NEJMoa2107322. Morris M, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. The Lancet 2024; doi: 10.1016/S0140-6736(24)01653-2. University of Chicago Medicine. Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto). Accessed June 18, 2024. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment [published correction appears in AJR Am J Roentgenol. 2017 Oct;209(4):949. doi: 10.2214/AJR.17.18875]. AJR Am J Roentgenol. 2017;209(2):277-288. doi:10.2214/AJR.17.18264 Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In: Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249 # # # Novartis Media Relations E-mail: [email protected] Novartis Investor RelationsCentral investor relations line: +41 61 324 7944 E-mail: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
2 hours ago
- Yahoo
Elon Musk just dropped 'Bitcoin-style' XChat, and the community is losing it
Elon Musk just dropped 'Bitcoin-style' XChat, and the community is losing it originally appeared on TheStreet. Elon Musk is doubling down on privacy. In his latest update for X (formerly Twitter), the billionaire CEO announced XChat — a new encrypted messaging feature that will support audio/video calls, vanishing messages, and all-file sharing. 'The all new XChat is rolling out with encryption, vanishing messages, and the ability to send any kind of file. Also, audio/video calling,' Musk posted on X. He added that the system is built on a 'whole new architecture' with 'Bitcoin-style encryption' — hinting at a more decentralized, cryptographically secure infrastructure, though no technical details were provided. The move is part of Musk's broader effort to transform X into a privacy-forward 'everything app.' While Musk didn't elaborate on what 'Bitcoin-style encryption' actually means, the phrase has sent crypto communities into full meltdown mode. 'Bro, if this is even half as secure as Bitcoin wallets, we're about to see Telegram get wrecked,' wrote one user on the CryptoLeaks Discord. "XChat + no phone number + vanishing mode?? Elon just gave OPSEC its biggest W,' said another in a Solana DEX server. A third user posted, 'You're telling me I can now send airdrop links, memes, and seed phrases without getting doxxed? God bless this man.' While announcing a separate payments feature X Money last week, which will launch in beta later this year — Musk emphasized the platform's cautious approach: 'This will be a very limited access beta at first. When people's saving are involved, extreme care must be taken.' The new wave of tools seems to suggest X wants to rival apps like Signal, Telegram, and even China's WeChat — combining finance, messaging, and social media under one encrypted roof. Elon Musk just dropped 'Bitcoin-style' XChat, and the community is losing it first appeared on TheStreet on Jun 1, 2025 This story was originally reported by TheStreet on Jun 1, 2025, where it first appeared. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 hours ago
- Yahoo
Scrub recap: overnight SpaceX rocket launch from Cape Canaveral delayed
Scrub recap: Scroll down to read updates from the scrubbed SpaceX Starlink 12-19 mission, which was set to liftoff early June 2. The next launch attempt is no earlier than 12:29 a.m. on June 3. Original story: Up late? SpaceX has plans to launch a rocket overnight. A Falcon 9 rocket is set to lift off on June 2 from Cape Canaveral Launch Complex 40 on the latest Starlink mission, which is being refered to as Starlink 12-19. SpaceX has confirmed liftoff is now targeted for 1:24 a.m. The Space Force 45th Weather Squadron predicts a 75% chance of favorable conditions for launch. It also states a low chance for poor weather in the booster recover area, which will stationed east of Florida in the Atlantic Ocean. According to Space Launch Delta 45, the rocket will travel on an eastern trajectory upon liftoff. This is a rare occasion as Starlink launches typically fly southeast or northeast. No middle-of-the-night sonic booms will be heard on the Space Coast, as the rocket's first stage will land on a SpaceX drone ship stationed out on the Atlantic Ocean. When is the next Florida launch? Is there a launch today? Upcoming SpaceX, Axiom, ULA rocket launch schedule at Cape Canaveral Countdown Timer Update 12:41 a.m.: SpaceX has updated that the launch is now no earlier than 12:29 a.m. on June 3. No official reason has been provided for the scrub. Update 12:35 a.m.: May 30 marked the five year anniversary of the first time Falcon 9 launched NASA astronauts aboard a SpaceX Dragon spacecraft. The Demo-2 mission certified the Dragon to fly NASA astronauts, but the spacecraft and Falcon 9 rocket have since flown three private missions as well. Update 12:20 a.m.: On May 27, Starship launched again from Texas on its ninth test flight. While the ship (upper stage) made it further than the previous two flights, it ended up in a spin which caused it to break apart over the Indian Ocean. SpaceX had also hoped to test the deployment of a payload, which were mockup Starlink satellites, on this mission. The payload door failed to open correctly. One thing which went correctly was the high quality footage beamed via Starlink. SpaceX posted the following images to X. Tonight's Falcon 9 liftoff is set for 1:24 a.m. Update 12:05 a.m.: Starlink posted a customer photo of Starlink service at work out on the water. SpaceX Starlink internet boasts service almost anywhere the sky is visible. This includes places where cell phone service isn't available. Tonight, 23 more Starlink satellites will be launching from Cape Canaveral. Update 11:54 p.m.: The 45th Weather Squadron predicted a 75% chance of favorable weather. The National Weather Service radar is currently clear. Skies over Brevard County are currently hazy. Brooke Edwards is a Space Reporter for Florida Today. Contact her at bedwards@ or on X: @brookeofstars. This article originally appeared on Florida Today: Scrub recap: SpaceX launch from Cape Canaveral scrubs early Monday
